Wednesday 29 April 2015

Alembic, Torrent soar on new drug approval

Both the stocks have soared over 10 percent after US FDA approved first generic versions of Abilify.

Alembic Pharmaceuticals
Alembic Pharma and Torrent Pharma are trading on a firm note following the early morning rally after the US FDA approved some of its new drugs.

According to a release issued on the US FDA (Food and Drug Administration) website, the US FDA has approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.

Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals and Torrent Pharmaceuticals have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms, the release added.

Alembic Pharma soared over 10 percent to touch a high at Rs. 496, and is now up 6.6 percent at Rs. 480. The counter has seen trades of around 73,000 shares as against the two-week daily average volume of around 48,000 shares on the BSE.

Torrent Pharma zoomed nearly 11 percent to a high of Rs. 1,323, and is now up 3.1 percent at Rs. 1,230. Around 26,000 shares have changed hands at the counter so far on the BSE, almost 3-times higher when compared with its two-week daily average volume of around 9,000-odd shares.

Meanwhile, the Sensex has recouped some of the losses and is now down 146 points at 27,251.

No comments:

Post a Comment